Federal Trade Commission Protecting America's Consumers
For Release: July 16, 1996
Quaker State Ads For Slick 50 Are False And Midleading, FTC CHARGES
The Federal Trade Commission has charged Quaker State - Slick 50, Inc., the manufacturer of Slick 50, the best-selling auto engine treatment in the U.S., with making false and unsubstantiated advertising claims. According to the FTC, ads for Slick 50 that tout tests showing improved engine performance are false and its claims of reduced engine wear are unsubstantiated.
Quaker State - Slick 50 is based in Houston, Texas. Since its 1978 introduction, Slick 50 has attracted about 30 million users world-wide. Slick 50 retails for about $18 a quart, and the company claims to have about 60% of the engine treatment market.
"Slick 50's ads claim that compared to motor oil alone, it reduces engine wear, lengthens engine life, and provides a host of other benefits. The claims sound good, but the evidence doesn't back them up,” said Jodie Bernstein, Director of the FTC's Bureau of Consumer Protection. “We believe the ads exaggerate the lack of protection motor oils provide modern engines at start-up, as well as the risk of premature engine failure. The premature engine failure Slick 50 claims to guard against is uncommon, and the company lacks reliable evidence it would be prevented by using Slick 50, in any case," she said. "In fact, all the evidence we've seen so far suggests that the best thing you can do for your car’s engine is to get an oil change performed at manufacturer recommended intervals," she said. "People who want to maximize their automobile performance and enhance its long life should read the owner's manual and follow the directions.”
Slick 50 is the most recent in a series of FTC cases challenging allegedly deceptive ad claims for oil additives or high octane fuel. “Last year, STP Corporation and its parent corporation, First Brands, paid an $888,000 civil penalty to settle FTC charges that they were making false and unsubstantiated claims for their engine treatment," Bernstein said.